Showing 3101-3120 of 8875 for: Cochrane Systematic Reviews Back
- Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke
Cochrane Systematic Reviews, 18-Feb-2014
Glycoprotein (GP) IIb-IIIa inhibitors are antiplatelet agents that act by antagonising GP IIb-IIIa receptors on the platelet surface and block the final common pathway to platelet aggregation by preventing the binding of fibrinogen molecules that form bri
- GM‐CSF (granulocyte macrophage colony‐stimulating factor) supplementation in culture media for women undergoing assisted reproduction
Cochrane Systematic Reviews, 16-Jul-2020
GM-CSF (granulocyte macrophage colony-stimulating factor) is a growth factor that is used to supplement culture media in an effort to improve clinical outcomes for those undergoing assisted reproduction. It is worth noting that the use of GM-CSF-supplemen
- Goal setting and strategies to enhance goal pursuit for adults with acquired disability participating in rehabilitation
Cochrane Systematic Reviews, 20-Jul-2015
Goal setting is considered a key component of rehabilitation for adults with acquired disability, yet there is little consensus regarding the best strategies for undertaking goal setting and in which clinical contexts. It has also been unclear what effect
- Gold as an oral corticosteroid sparing agent in stable asthma
Cochrane Systematic Reviews, 23-Oct-2000
Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of steroids is associated with serious side effects. Physicians treating such patients continue to search for alternative therapies that
- Golimumab for rheumatoid arthritis
Cochrane Systematic Reviews, 20-Jan-2010
Golimumab is a humanized inhibitor of Tumor necrosis factor-alpha, recently approved by the Food and Drug Administration (FDA) for the treatment of Rheumatoid arthritis (RA).
- Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome
Cochrane Systematic Reviews, 24-Aug-2015
Approximately 15% of women with PCOS remain anovulatory despite treatment with oral anti-oestrogen medications such as clomiphene citrate. In addition, about half of women with PCOS ovulating on anti-oestrogen treatment fail to conceive. Gonadotrophin sti
- Gonadotrophin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles
Cochrane Systematic Reviews, 17-Jul-2008
Gonadotropin releasing hormone agonists (GnRHa) are used in assisted reproduction cycles to reversibly block pituitary function and prevent a luteinizing hormone surge. In the short and ultrashort protocols of GnRHa administration, injection of gonadotrop
- Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Cochrane Systematic Reviews, 9-Nov-2015
Gonadotrophin-releasing hormone agonists (GnRHa) are commonly used in assisted reproduction technology (ART) cycles to prevent a luteinising hormone surge during controlled ovarian hyperstimulation (COH) prior to planned oocyte retrieval, thus optimising
- Gonadotrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome
Cochrane Systematic Reviews, 17-Jul-2008
Elevation of endogenous LH levels may result in premature luteinization. This may also be associated with the increased rate of spontaneous abortion. Gonadotropin releasing hormone analogue (GnRHa) used prior to human menopausal gonadotropin (hMG/FSH) adm
- Gonadotrophin‐releasing hormone analogues for endometriosis: bone mineral density
Cochrane Systematic Reviews, 20-Oct-2003
Gonadotrophin-releasing hormone analogues (GnRHas) are generally well tolerated, and are effective in relieving the symptoms of endometriosis (Prentice 2003). Unfortunately the low oestrogen state that they induce is associated with adverse effects includ
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Cochrane Systematic Reviews, 1-Nov-2010
Endometriosis is a common gynaecological condition, characterised by the presence of endometrial tissue in sites other than the uterine cavity (excluding adenomyosis) that frequently presents with pain. The gonadotrophin-releasing hormone analogues (GnRHa
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Cochrane Systematic Reviews, 16-Mar-2010
Endometriosis is a common gynaecological condition that frequently presents with the symptom of pain. The precise pathogenesis (mode of development) of endometriosis is unclear but it is evident that endometriosis arises by the dissemination of endometriu
- Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology
Cochrane Systematic Reviews, 29-Apr-2016
Gonadotrophin-releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo-oestrogenic side-effects, flare-up, or long down-regulation period associated with
- Gonadotrophins for idiopathic male factor subfertility
Cochrane Systematic Reviews, 18-Aug-2013
Male factors leading to subfertility account for at least half of all cases of subfertility worldwide. Although some causes of male subfertility are treatable, treatment of idiopathic male factor subfertility remains empirical. Researchers have used gonad
- Gonadotrophins for ovulation induction in women with polycystic ovary syndrome
Cochrane Systematic Reviews, 16-Jan-2019
Ovulation induction with follicle stimulating hormone (FSH) is a second-line treatment in women with polycystic ovary syndrome (PCOS) who do not ovulate or conceive on clomiphene citrate.
- Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology
Cochrane Systematic Reviews, 31-Oct-2014
Human chorionic gonadotropin (HCG) is routinely used for final oocyte maturation triggering in in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) cycles, but the use of HCG for this purpose may have drawbacks. Gonadotropin-releasing horm
- Governance arrangements for health systems in low‐income countries: an overview of systematic reviews
Cochrane Systematic Reviews, 12-Sep-2017
Governance arrangements include changes in rules or processes that determine authority and accountability for health policies, organisations, commercial products and health professionals, as well as the involvement of stakeholders in decision-making. Chan
- Government regulation of private health insurance
Cochrane Systematic Reviews, 22-Feb-2021
The strain on public resources to meet the healthcare needs of populations through publicly-provided health insurance programmes is increasing and many governments turn to private health insurance (PHI) to ease the pressure on government budgets. With the
- Gowning by attendants and visitors in newborn nurseries for prevention of neonatal morbidity and mortality
Cochrane Systematic Reviews, 22-Apr-2003
Overgowns are widely used in newborn nurseries and neonatal intensive care units. It is thought that gowns may help to prevent the spread of nosocomial infection and serve as a reminder to staff and visitors to wash their hands before contact with the inf
- Gradual versus abrupt discontinuation of oxygen in preterm or low birth weight infants
Cochrane Systematic Reviews, 23-Oct-2001
The issue of whether to abruptly or gradually discontinue supplemental oxygen is a contentious one. There have been mixed results in studies of both humans and animal models on the effects of either method of oxygen cessation on important infant outcomes.
